Review of a new bone tumor therapy strategy based on bifunctional biomaterials

• 作者: Jinfeng Liao Ruxia Han Yongzhi Wu Zhiyong Qian
• 来源期刊: 骨研究（英文版）
• 年，卷（期）: 2021,（2）
• 所属期刊栏目: REVIEWS
• 页码范围: 153-165
• 页数: 13页
• 语种: 英文

摘要

INTRODUCTION Bone tumors involve the invasion of tumors into bone tissue and are classified as either primary tumors or metastatic tumors. Osteosarcoma is a well-known primary malignant bone tumor that often occurs in children and adolescents. It has been reported that this disease has become the second leading cause of tumor-related death in young teenagers.1 The majority of patients die from lung metastases. Its annual incidence worldwide is ～1–3 cases per million.2 The clinical signs of osteosarcoma are not obvious without spontaneous fracture or severe pain early on. Therefore, this disease is not easily diagnosed, but the tumors grow quickly. As a result, osteosarcoma causes a large bone defect and limitations in motion and can metastasize to the lungs.3 The etiology of osteosarcoma is still not clear.4 To date, the most common clinical treatment methods for bone tumors include chemotherapy, wide surgical resection, and radiotherapy.5 How-ever, osteosarcoma is not sensitive to radiotherapy and is prone to chemotherapy resistance. Surgical resection often fails to com-pletely remove the tumor, which is the main cause of post-operative recurrence and metastasis. Moreover, osteosarcoma invades large areas of bone, which cannot repair itself, and has serious effects on the quality of life of patients.6 The 5-year survival rate of patients with osteosarcoma is ～60％.7 Unfortu-nately, advances in osteosarcoma treatment have reached a plateau over the past 40 years.